CN111732608A - 一种基于邻菲罗啉的羰基锰化合物、制备方法及应用 - Google Patents
一种基于邻菲罗啉的羰基锰化合物、制备方法及应用 Download PDFInfo
- Publication number
- CN111732608A CN111732608A CN202010694146.6A CN202010694146A CN111732608A CN 111732608 A CN111732608 A CN 111732608A CN 202010694146 A CN202010694146 A CN 202010694146A CN 111732608 A CN111732608 A CN 111732608A
- Authority
- CN
- China
- Prior art keywords
- phenanthroline
- manganese
- compound
- carbonyl
- carbon monoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 title claims abstract description 31
- QKOHYQVZNLEAJH-UHFFFAOYSA-N oxomethylidenemanganese Chemical compound O=C=[Mn] QKOHYQVZNLEAJH-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 9
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 28
- QFEOTYVTTQCYAZ-UHFFFAOYSA-N dimanganese decacarbonyl Chemical group [Mn].[Mn].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] QFEOTYVTTQCYAZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000011572 manganese Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 9
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003446 ligand Substances 0.000 abstract description 6
- 229910052748 manganese Inorganic materials 0.000 abstract description 6
- NSMJMUQZRGZMQC-UHFFFAOYSA-N 2-naphthalen-1-yl-1H-imidazo[4,5-f][1,10]phenanthroline Chemical compound C12=CC=CN=C2C2=NC=CC=C2C2=C1NC(C=1C3=CC=CC=C3C=CC=1)=N2 NSMJMUQZRGZMQC-UHFFFAOYSA-N 0.000 abstract description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000003578 releasing effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102000016761 Haem oxygenases Human genes 0.000 description 2
- 108050006318 Haem oxygenases Proteins 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- -1 i.e. Chemical compound 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
技术领域
本发明属于医药化学技术领域,具体涉及一种基于邻菲罗啉的羰基锰化合物、制备方法及应用。
背景技术
一氧化碳(carbon monoxide,CO)是一种致命的毒性气体,但1991年Mark等发现CO在生物体内具有重要的生理功能,这是继NO之后发现的第二种气体信使分子,同时也是一种神经递质。研究发现,一氧化碳作为一种细胞信使分子在生物体内具有舒张血管和支气管平滑肌、抑制血小板聚集、抑制炎症反应、抗氧化、抗凋亡、抗增殖等多种生理学作用,在神经、呼吸、循环等生理过程和抑制急性肺损伤、脏器缺血再灌注损伤、器官移植排斥反应等病理过程中也发挥着重要调节作用。有动物实验研究表明CO在特定的条件下,对包括氧超载或者机械通气造成的肺损伤、脓毒症、间质性肺纤维化,以及肺移植后排斥具有一定的治疗作用。目前把CO用于治疗的方案有:(1)直接吸入一定浓度的CO;(2)服用可以被肝脏内的酶催化产生CO的前体药(如methylene chloride);(3)用特殊的CO载体把CO送入到体内。内源性CO主要来源于血红素氧合酶(hemeoxygenase,HO)对血红素的分解(约85%),具有抗炎症、抗氧化以及抗细胞凋亡的作用,外源性小剂量的CO也能发挥相同的作用。
虽然外源性CO可以籍直接吸入CO气体来获得,但其缺点是必须经过整个呼吸系统,再经血液循环抵达相关组织,这对于只需局部发挥作用的情形是不合适的,如器官移植。过渡金属羰基化合物是一类金属有机化合物,在适当的条件下其中的羰基(CO)能够离去,如光照、取代反应、氧化还原诱导等。利用金属羰基化合物的这些性质可以设计、合成一些特定的过渡金属羰基化合物,使之在合适的条件下释放CO,即一氧化碳释放剂(分子)(carbon monoxide-releasing molecules,CORM)。CORM的优点是既无需通过机体代谢过程,也无需经呼吸系统吸入而直接在用药部位注射给药释放CO,此外,用量大小和用药时机控制也容易掌握。这些都为临床治疗及直接研究外源性CO对机体组织应激损伤的作用机制提供了方便。
与其他诱导方式相比,光诱导在一氧化碳释放时间和地点上更易控制,近年来受到科学家的广泛关注。目前,大部分光诱导的一氧化碳释放剂需要高能量,短波长的光来诱导一氧化碳释放,但是这类光很难穿透皮肤,并且可能对身体有害。因此需要开发长波长的可见光或近红外光诱导一氧化碳释放。锰是人体必需的微量元素,在维持人身体健康方面发挥着重要作用,主要有以下几点:促进骨骼的正常生长和发育;维持正常的糖代谢和脂肪代谢;维持正常脑功能;抗衰老、抗氧化;预防癌症等。因此,基于锰的金属羰基化合物作为光诱导的一氧化碳释放剂受到科学家的广泛关注。现有的羰基锰化合物一氧化碳释放剂光诱导产生一氧化碳所需的光源大部分为紫外光,但是对于利用可见光或近红外光诱导的一氧化碳释放效果较差。
发明内容
为了解决上述问题,本发明提供一种基于邻菲罗啉的羰基锰化合物、制备方法及应用。本发明通过选择具有较大共轭体系的邻菲罗啉衍生物配体,与五羰基溴化锰作用得到了相应的羰基锰化合物,该化合物在可见光区(400-500nm)具有较强的紫外吸收,可以在蓝光作用下分解释放一氧化碳,可以作为可见光诱导的一氧化碳释放剂。
本发明第一个目的提供一种基于邻菲罗啉的羰基锰化合物,具有如式(Ⅰ)所示的结构,
本发明第二个目的提供一种基于邻菲罗啉的羰基锰化合物的制备方法,包括以下步骤:
将式(Ⅱ)化合物分散于有机溶剂中,避光回流加热,待溶液回流时加入Mn(CO)5Br,回流反应2~3h后,冷却,抽滤,即得式(Ⅰ)基于邻菲罗啉的羰基锰化合物;其合成路线如下:
优选的,所述式(Ⅱ)化合物与所述Mn(CO)5Br的摩尔比为1:1。
优选的,所述有机溶剂为二氯甲烷。
更优选的,所述式(Ⅱ)化合物与所述有机溶剂质量比为1:200~400。
本发明第三个目的提供一种基于邻菲罗啉的羰基锰化合物在光诱导一氧化碳释放中的应用。
与现有技术相比,本发明的有益效果在于:
本发明选择具有较大共轭体系的邻菲罗啉衍生物配体与五羰基溴化锰作用得到相应的羰基锰化合物,该化合物可以在可见光(LED蓝光)作用下分解释放一氧化碳,克服了羰基锰化合物在紫外光作用下诱导产生一氧化碳的缺点,实现可见光诱导的一氧化碳释放。
本发明提供的制备方法在回流状态下加入Mn(CO)5Br固体,不需要惰性气体保护也可完成,且可以得到很高的反应收率,方便易行。
附图说明
图1实施例1提供的基于邻菲罗啉的羰基锰化合物在LED蓝光照射下红外羰基特征峰随时间变化图
具体实施方式
为了使本领域技术人员更好地理解本发明的技术方案能予以实施,下面结合具体实施例和附图对本发明作进一步说明,但所举实施例不作为对本发明的限定。
本发明提供的一种基于邻菲罗啉的羰基锰化合物,具有如式(Ⅰ)所示的结构,
本发明通过选择具有较大共轭体系的邻菲罗啉衍生物配体,与五羰基溴化锰作用得到了相应的羰基锰化合物,该化合物可以在可见光(LED蓝光)作用下分解释放一氧化碳,克服了羰基锰化合物在紫外光作用下诱导产生一氧化碳的缺点,实现可见光诱导的一氧化碳释放。
实施例1
一种基于邻菲罗啉的羰基锰化合物,具有如式(Ⅰ)所示的结构,
上述所述的式(Ⅰ)基于邻菲罗啉的羰基锰化合物具体制备方法如下:
将式(Ⅱ)配体苯基咪唑并[5,6-f]邻菲罗啉(133mg,0.45mmol)置于二氯甲烷(26.2g)中回流加热,用锡箔纸将反应瓶包住来避光,待溶液回流后加入Mn(CO)5Br(124mg,0.45mmol),反应0.5h后即产生大量黄色沉淀,将该混合溶液继续回流反应2h,然后置于冰箱中冷却,最后抽滤得产生黄色粉末状固体(200mg,产率80%),即得式(Ⅰ)基于邻菲罗啉的羰基锰化合物;
其合成路线如下:
1H NMR(400MHz,DMSO):9.47(d,J=4.2Hz,2H),9.14(d,J=8.4Hz,2H),8.29(d,J=7.6Hz,2H),8.10(s,2H),7.61(t,J=7.5Hz,2H),7.53(d,J=7.0Hz,1H)。
实施例2
一种基于邻菲罗啉的羰基锰化合物,具有如式(Ⅰ)所示的结构,
上述所述的式(Ⅰ)基于邻菲罗啉的羰基锰化合物具体制备方法如下:
将式(Ⅱ)配体苯基咪唑并[5,6-f]邻菲罗啉(133mg,0.45mmol)置于二氯甲烷(53.2g)中回流加热,用锡箔纸将反应瓶包住来避光,待溶液回流后加入Mn(CO)5Br(124mg,0.45mmol),反应1h后即产生大量黄色沉淀,将该混合溶液继续回流反应2h,然后置于冰箱中冷却,最后抽滤得产生黄色粉末状固体,即得式(Ⅰ)基于邻菲罗啉的羰基锰化合物;
其合成路线如下:
为了说明本发明提供的基于邻菲罗啉的羰基锰化合物性能,仅对实施例1提供的基于邻菲罗啉的羰基锰化合物在LED蓝光照射下释放一氧化碳的相关性能进行测试IR(DMSO,υ/cm-1),见图1。
图1实施例1提供的基于邻菲罗啉的羰基锰化合物在LED蓝光照射下红外羰基特征峰随时间变化图;
从图1中可知,实施例1提供的基于邻菲罗啉的羰基锰化合物在2023、1931和1915cm-1有三个明显的羰基红外特征吸收峰,在LED蓝光照射下这些红外羰基特征峰迅速下降,说明化合物的羰基在光照下分解作为一氧化碳释放出来,并在1973cm-1和1868cm-1处出现两个新的红外峰,1973cm-1处吸收峰逐渐增强,而1868cm-1处吸收峰先增强后逐渐减弱并且变为1877cm-1和1853cm-1处的两个峰,而且位于1931和1915cm-1处的两个特征峰也逐渐转变为一个单峰;因此,该羰基锰化合物最后分解为在1973、1931、1877cm-1和1853cm-1处有四个羰基特征峰的产物,该过程中不断有气泡冒出,即为释放的一氧化碳气体,该分解过程很快,五分钟左右即分解完全,溶液由最初的黄色变为无色,可以作为光诱导的一氧化碳释放剂,如果采用较低能量的光源,如绿光或红光,即可以减慢化合物光照分解的速度。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内也视同包含这些改动和变型在内。
Claims (6)
3.根据权利要求2所述的基于邻菲罗啉的羰基锰化合物的制备方法,其特征在于,所述式(Ⅱ)化合物与所述Mn(CO)5Br的摩尔比为1:1。
4.根据权利要求2所述的基于邻菲罗啉的羰基锰化合物的制备方法,其特征在于,所述有机溶剂为二氯甲烷。
5.根据权利要求4所述的基于邻菲罗啉的羰基锰化合物的制备方法,其特征在于,所述式(Ⅱ)化合物与所述有机溶剂质量比为1:200~400。
6.一种权利要求1所述的基于邻菲罗啉的羰基锰化合物在光诱导一氧化碳释放中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010694146.6A CN111732608B (zh) | 2020-07-17 | 2020-07-17 | 一种基于邻菲罗啉的羰基锰化合物、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010694146.6A CN111732608B (zh) | 2020-07-17 | 2020-07-17 | 一种基于邻菲罗啉的羰基锰化合物、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111732608A true CN111732608A (zh) | 2020-10-02 |
CN111732608B CN111732608B (zh) | 2023-05-23 |
Family
ID=72655896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010694146.6A Active CN111732608B (zh) | 2020-07-17 | 2020-07-17 | 一种基于邻菲罗啉的羰基锰化合物、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111732608B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898351A (zh) * | 2021-01-25 | 2021-06-04 | 嘉兴学院 | 光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
CN114315908A (zh) * | 2022-01-06 | 2022-04-12 | 嘉兴学院 | 一种光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749349A (zh) * | 2016-11-24 | 2017-05-31 | 吉林师范大学 | 基于混合n,o‑配体的过渡金属配合物的制备方法、晶体结构及其应用 |
-
2020
- 2020-07-17 CN CN202010694146.6A patent/CN111732608B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749349A (zh) * | 2016-11-24 | 2017-05-31 | 吉林师范大学 | 基于混合n,o‑配体的过渡金属配合物的制备方法、晶体结构及其应用 |
Non-Patent Citations (4)
Title |
---|
HAI-LIN ZHANG 等: "Visible light-controlled carbon monoxide delivery combined with the inhibitory activity of histone deacetylases from a manganese complex for an enhanced antitumor therapy", 《JOURNAL OF INORGANIC BIOCHEMISTRY》 * |
JEREMIE ROSSIER 等: "Cytotoxicity of Mn-based photoCORMs of ethynyl-α-diimine ligands against different cancer cell lines: The key role of CO-depleted metal fragments", 《JOURNAL OF INORGANIC BIOCHEMISTRY》 * |
JORGE JIMENEZ 等: "Synthesis and assessment of CO-release capacity of manganese carbonyl complexes derived from rigid α-diimine ligands of varied complexity", 《EUR. J. INORG. CHEM.》 * |
张俊蝶 等: "光诱导锰羰基化合物释放一氧化碳研究", 《化学试剂》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898351A (zh) * | 2021-01-25 | 2021-06-04 | 嘉兴学院 | 光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
CN112898351B (zh) * | 2021-01-25 | 2024-04-12 | 嘉兴学院 | 光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
CN114315908A (zh) * | 2022-01-06 | 2022-04-12 | 嘉兴学院 | 一种光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
CN114315908B (zh) * | 2022-01-06 | 2024-04-05 | 嘉兴学院 | 一种光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111732608B (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111732608B (zh) | 一种基于邻菲罗啉的羰基锰化合物、制备方法及应用 | |
Hua et al. | Composition‐Dependent enzyme mimicking activity and radiosensitizing effect of bimetallic clusters to modulate tumor hypoxia for enhanced cancer therapy | |
CN112245579B (zh) | 一种缓解肿瘤乏氧的光动力治疗剂及其制备方法和应用 | |
Lin et al. | Light amplified oxidative stress in tumor microenvironment by carbonized hemin nanoparticles for boosting photodynamic anticancer therapy | |
Streciwilk et al. | Synthesis and cytotoxicity studies of p-benzyl substituted NHC–copper (I) bromide derivatives | |
Geetha et al. | Coumarin substituted 4–aryl–1, 2, 4–triazolium salts and their silver (I) N–heterocyclic carbene complexes: effects of counterions on the antioxidant and antihaemolytic properties | |
Gong et al. | Oxidization enhances type I ROS generation of AIE-active zwitterionic photosensitizers for photodynamic killing of drug-resistant bacteria | |
CN113461740B (zh) | 一种铱配合物及其制备方法和应用 | |
CN112898351A (zh) | 光诱导锰羰基化合物一氧化碳释放剂及其制备方法和应用 | |
CN110372754A (zh) | 一种新型金属铱配合物及其制备方法和应用 | |
CN113831351A (zh) | 一类新型四吡咯衍生物及其应用 | |
CN101695502B (zh) | 镧富勒醇及其在制备抑制肿瘤生长药物中的应用 | |
CN108864117A (zh) | 一类二苯基二氢卟吩化合物及其制备方法与应用 | |
CN112812121A (zh) | 一种吡啶酮修饰锌酞菁及其制备方法和应用 | |
CN112121154A (zh) | 一种肿瘤微环境响应的co气体治疗剂及其制备和应用 | |
CN110423260A (zh) | 一种葡萄糖修饰的环金属化铱光敏剂及其制备方法和应用 | |
AU2021362841B2 (en) | Hexadecylammonium group-modified phthalocyanine, and preparation method therefor and application thereof as photodynamic drug | |
CN105837583B (zh) | 卟烯‑铱金属配合物及其制备方法和应用 | |
CN103073553A (zh) | 水溶性萘菁基化合物、制备方法及作为光敏剂的应用 | |
CN113144175A (zh) | 一种肿瘤微环境响应的co气体治疗剂及其制备方法和应用 | |
RU2429242C2 (ru) | Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства | |
CN107840837A (zh) | 一种染料木素铁螯合物及其制备方法与用途 | |
CN111808144A (zh) | 一种基于d-a-d结构的具有近红外光吸收的金属类配合物及其应用 | |
CN106748973A (zh) | 两种叠氮化药物及其制备方法和应用 | |
CN117209541A (zh) | 一种水溶性锰羰基化合物一氧化碳释放剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |